Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Organigram Holdings (OGI) Declines -34.9% Over 30 Days Amid Cannabis Sector Pressures

Organigram Holdings (OGI) Declines -34.9% Over 30 Days Amid Cannabis Sector Pressures

Key Takeaways

  • Organigram Holdings shares declined approximately 34.9% over the last 30 days, falling from a closing price of about $0.94 on October 21, 2026, to roughly $0.61.
  • The pullback extends a longer downtrend, with the stock down roughly 49% over the last quarter from about $1.20.
  • Selling accelerated in mid-November, when the stock slid from about $0.83 to the $0.61 area within a matter of days.
  • Several down days were accompanied by elevated trading volume, pointing to increased selling pressure rather than quiet drift.
  • Broader cannabis-sector headwinds, including regulatory uncertainty and capital-market pressures common to small-cap producers, continue to weigh on sentiment.

Organigram Holdings (OGI) Company Background

Organigram Holdings Inc. is a Canadian licensed producer of cannabis headquartered in Moncton, New Brunswick. The company cultivates, processes, and sells recreational and medical cannabis, distributing products across Canada and into select international markets. Its portfolio includes well-known brands such as SHRED, Edison, Big Bag O' Buds, Monjour, and Trailblazer, which span dried flower, pre-rolls, vapes, edibles, and derivative products.

Organigram has pursued a diversified growth strategy, including international expansion and a strategic partnership with British American Tobacco through the latter's investment arm. I follow the stock closely because of its position within the Canadian legal cannabis market, its brand portfolio, and its exposure to evolving regulatory and competitive dynamics across North America and abroad. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

OGI Stock Performance: 30-Day and Quarterly Declines

Over the last 30 days, OGI shares have fallen sharply. From a closing price of $0.9406 on October 21, 2026, the stock declined to roughly $0.61, a drop of about 34.9%. The move was not uniform; the most pronounced leg lower occurred in mid-November, when the stock broke below $0.80 and continued toward the $0.61 area in a span of several trading sessions.

The quarterly picture reinforces the negative trend. Roughly three months ago, the stock was trading near $1.20, meaning it has lost about 49% over the quarter. The stock reached a multi-month high around $1.29 in mid-August before reversing into a sustained decline that carried through September, October, and November. This pattern indicates persistent selling pressure rather than a single isolated shock. From what I see, the volume data supports the view that this was not a quiet drift.

Factors Behind the Recent 30-Day Drop

The 30-day decline reflects a combination of sector-level pressures and stock-specific selling activity. On a technical basis, elevated trading volume accompanied several of the steepest down days, particularly in early and mid-November, suggesting that institutional and retail sellers were actively reducing positions.

Within the cannabis sector, producers continue to contend with regulatory uncertainty, pricing competition, and limited access to capital — conditions that frequently translate into volatility for small- and mid-cap operators. Organigram's share price has also been subject to broader market sentiment shifts affecting Canadian cannabis equities as a group.

Because specific company catalysts can move small-cap stocks materially, investors should consult Organigram's official filings and disclosures for the most current operational and financial updates rather than relying on price action alone. What is clear from the data is that the downward momentum intensified in the second half of the 30-day window, with the steepest declines concentrated in the most recent trading sessions.

Quarterly Performance Drivers

The quarterly trend tells a story of fading momentum after an early-August rally. In mid-August, the stock spiked to roughly $1.29 on unusually heavy volume, briefly attracting significant buying interest. That move was followed by a steady, multi-week retreat that erased the gains and carried the stock below $1.00 by early October.

Over the remainder of the quarter, the stock continued to grind lower, with intermittent bounces failing to hold. The sustained decline suggests that sellers remained in control and that any near-term rallies were met with renewed selling. For a company of Organigram's size, broader sector sentiment, balance-sheet considerations, and the pace of progress toward profitability are recurring themes that tend to influence how the market prices the shares over multi-month horizons.

OGI Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors are likely to shape the trajectory of OGI shares. Quarterly earnings releases and management guidance will remain central, as investors assess revenue growth, margins, and progress toward profitability. Updates on international expansion, product launches, and any developments related to strategic partnerships may also influence sentiment.

At the sector level, regulatory developments in key markets, shifts in consumer demand, and the broader availability of capital for cannabis operators will be important to monitor. Competitive pricing pressure within the Canadian market and the pace of any industry consolidation could further affect the stock. Investors should track these fundamentals alongside official company disclosures, as the factors above are presented for informational purposes and do not constitute financial advice. I'm watching this closely as the next earnings cycle approaches.

Exploring Tickeron AI Tools for Market Insights

In my own research process, I turn to Tickeron’s suite of AI tools to supplement fundamental and technical analysis. The AI Trading Bots platform, for instance, lets me review how automated strategies are positioned across thousands of tickers, including those in the cannabis space. These tools provide data-driven perspectives that help clarify whether current price action aligns with broader patterns. I find them especially useful when evaluating small-cap names like OGI where sentiment can shift quickly.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OGI

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for OGI turns negative, indicating new downward trend

OGI saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 85 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for OGI turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 38 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for OGI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where OGI advanced for three days, in 169 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

OGI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.260) is normal, around the industry mean (6.379). P/E Ratio (1.435) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.650) is also within normal values, averaging (183.387).

The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. OGI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -7%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 411%, while BFRI experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 8 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which, engages in the production and sale of medical marijuana

Industry PharmaceuticalsGeneric

Industry
N/A
Address
145 King Street West
Phone
+1 506 232-4400
Employees
1154
Web
https://www.organigram.ca
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.